Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA)
- PMID: 24562443
- DOI: 10.1093/annonc/mdu086
Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA)
Abstract
Background: Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival.
Patients and methods: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models.
Results: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated.
Conclusion: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.
Keywords: cachexia; cancer; classification; validation.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
'Pre-cachexia': a non-existing phenomenon in cancer?Ann Oncol. 2014 Aug;25(8):1668-9. doi: 10.1093/annonc/mdu178. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827129 No abstract available.
Similar articles
-
Definition and classification of cancer cachexia: an international consensus.Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. Lancet Oncol. 2011. PMID: 21296615 Review.
-
The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis.J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):789-797. doi: 10.1002/jcsm.12220. Epub 2017 Jun 18. J Cachexia Sarcopenia Muscle. 2017. PMID: 28627024 Free PMC article.
-
Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer.Nutr Cancer. 2018 Nov-Dec;70(8):1322-1329. doi: 10.1080/01635581.2018.1504092. Epub 2018 Sep 20. Nutr Cancer. 2018. PMID: 30235002 Clinical Trial.
-
Measuring cachexia-diagnostic criteria.Ann Palliat Med. 2019 Jan;8(1):24-32. doi: 10.21037/apm.2018.08.07. Epub 2018 Sep 7. Ann Palliat Med. 2019. PMID: 30525765 Review.
-
Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? - analysis from a multicenter cross sectional study.Acta Oncol. 2014 Apr;53(4):539-46. doi: 10.3109/0284186X.2013.823239. Epub 2013 Sep 2. Acta Oncol. 2014. PMID: 23998647
Cited by
-
Targeting cancer cachexia: Molecular mechanisms and clinical study.MedComm (2020). 2022 Sep 10;3(4):e164. doi: 10.1002/mco2.164. eCollection 2022 Dec. MedComm (2020). 2022. PMID: 36105371 Free PMC article. Review.
-
Skeletal Muscle-Adipose Tissue-Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer.Int J Mol Sci. 2021 Apr 25;22(9):4469. doi: 10.3390/ijms22094469. Int J Mol Sci. 2021. PMID: 33922898 Free PMC article. Review.
-
Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma.Hematol Oncol. 2022 Aug;40(3):320-331. doi: 10.1002/hon.3002. Epub 2022 Apr 18. Hematol Oncol. 2022. PMID: 35398917 Free PMC article. Review.
-
Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review).Mol Med Rep. 2020 Dec;22(6):4967-4980. doi: 10.3892/mmr.2020.11608. Epub 2020 Oct 16. Mol Med Rep. 2020. PMID: 33174001 Free PMC article. Review.
-
A systematic review of herbal medicines for the treatment of cancer cachexia in animal models.J Zhejiang Univ Sci B. 2019 Jan.;20(1):9-22. doi: 10.1631/jzus.B1800171. J Zhejiang Univ Sci B. 2019. PMID: 30614226 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources